ロベナコキシブ
Robenacoxib
5-ethyl-2-[(2,3,5,6-tetrafluorophenyl)amino]phenyl acetic acid
別名: Onsior · robenacoxibum · robénacoxib
VetSheet 獣医チームが監修更新日 2026年4月5日エビデンスに基づく獣医学リファレンス
用量は獣医専門家向けの臨床参考資料です。必ず最新の医薬品情報および個別症例に基づいて確認してください。
動物種別用量
🌎 NA — North America🌍 EU — Europe
犬
| 適応 | 用量 | 経路 | 頻度 | 期間 | 地域 |
|---|---|---|---|---|---|
| Pain and inflammation associated with chronic osteoarthritis | 1 mg/kg with a range of 1-2 mg/kg | PO | once daily | Discontinue after 10 days if no clinical improvement seen | 🌎 NA |
| Pain and inflammation associated with orthopedic or soft tissue surgery | 2 mg/kg | SC | once | — | 🌎 NA |
| Perioperative analgesia (orthopaedic and soft tissue surgery) | 2 mg/kg | SC | q24h | Maximum of 2 doses | 🌍 EU |
| Acute and chronic musculoskeletal disorders | 1-2 mg/kg | PO | q24h | Discontinue after 10 days if no clinical improvement | 🌍 EU |
- Pain and inflammation associated with chronic osteoarthritis: Give at the same time every day. For long term treatment, can adjust to lowest effective dose.
- Pain and inflammation associated with orthopedic or soft tissue surgery: Administer approximately 30 minutes before the start of surgery.
- Perioperative analgesia (orthopaedic and soft tissue surgery): Administer approximately 30 minutes before the start of surgery.
- Acute and chronic musculoskeletal disorders: Do not administer with food. Monitoring is recommended for long-term treatment (>12 weeks).
猫
| 適応 | 用量 | 経路 | 頻度 | 期間 | 地域 |
|---|---|---|---|---|---|
| Acute pain and inflammation associated with musculoskeletal disorders | 1 mg/kg; with a range of 1-2.4 mg/kg | PO | once daily | up to 6 days | 🌎 NA |
| Pain and inflammation associated with chronic osteoarthritis (Note: Label likely intended for surgical pain based on injection formulation) | 2 mg/kg | SC | once | — | 🌎 NA |
| Perioperative analgesia | 2 mg/kg | SC | q24h | Maximum of 2 doses | 🌍 EU |
| Acute and chronic musculoskeletal pain and inflammation | 1-2 mg/kg | PO | q24h | As directed by veterinarian | 🌍 EU |
- Acute pain and inflammation associated with musculoskeletal disorders: Equates to 1 tablet for cats weighing 2.5-<6 kg and 2 tablets for cats weighing 6 kg-<12 kg. Give either without food or with a small amount of food; tablets should not be divided or broken.
- Pain and inflammation associated with chronic osteoarthritis (Note: Label likely intended for surgical pain based on injection formulation): Administer approximately 30 minutes before the start of surgery.
- Perioperative analgesia: Administer approximately 30 minutes before the start of surgery.
- Acute and chronic musculoskeletal pain and inflammation: May be mixed with a small amount of food. Monitoring is recommended for long-term treatment (>12 weeks).
用量は獣医専門家向けの臨床参考資料です。必ず最新の医薬品情報および個別症例に基づいて確認してください。
概要
ロベナコキシブ (Robenacoxib) は、犬および猫用に特別に認可された高選択的コキシブ系非ステロイド性抗炎症薬（NSAID）です。
主な臨床的特徴：
- 組織選択性：血中からは速やかに消失する一方で、活動性の炎症部位（炎症を起こした関節など）には高濃度で長時間とどまるという独自の薬物動態プロファイルを示します。この「組織特異的」な作用により、全身性の副作用を最小限に抑えつつ有効性を最大化します。
- 高いCOX-2選択性：COX-1と比較して、犬では約140倍、猫では約500倍のCOX-2選択性を示し、獣医療において最もCOX-2に特異的なNSAIDの一つです。
- 適応症：主に犬の慢性変形性関節症の疼痛管理、猫の急性筋骨格系疼痛、および両動物種の軟部組織または整形外科手術に伴う周術期疼痛の管理に使用されます。
作用機序
Robenacoxib exerts its anti-inflammatory and analgesic effects by selectively inhibiting the Cyclooxygenase-2 (COX-2) enzyme.
Arachidonic Acid → COX-2 Enzyme → Prostaglandin E2 (PGE2) and other inflammatory mediators.
By specifically targeting the inducible COX-2 isoform, robenacoxib effectively blunts the production of prostaglandins responsible for pain, inflammation, and fever. Because it largely spares the constitutive COX-1 enzyme, it preserves the homeostatic prostaglandins that are crucial for maintaining gastrointestinal mucosal integrity, renal blood flow, and normal platelet function.
安全性・警告
禁忌
- Patients with active gastrointestinal ulcers
- Hypersensitivity to robenacoxib or its excipients
- Dogs with hepatic disease
- Dehydrated, hypovolaemic, or hypotensive patients
- Patients with pre-existing gastrointestinal disease or ulceration
- Patients with blood clotting disorders
- Pregnant or lactating animals
- Dogs < 12 weeks of age or < 2.5 kg body weight
- Cats < 16 weeks of age or < 2.5 kg body weight
- Perioperative use in animals with renal disease (not advisable)
有害事象
- Decreased appetite
- Blood in feces (melena/hematochezia)
- Mild gastrointestinal signs (vomiting, soft feces, diarrhea)
- Gastrointestinal ulceration or bleeding (rare but severe)
- Renal toxicity (especially if hypotensive or dehydrated)
- Hepatic accumulation (in patients with pre-existing liver disease)
注意事項
Strict Veterinary Monitoring Required: Use with extreme caution in patients with impaired cardiac or renal function, dehydration, hypovolemia, hypotension, or in cats with hepatic dysfunction.
- Washout Period: Do not use concurrently with corticosteroids or other NSAIDs. A treatment-free period of at least 24 hours (accounting for the half-life of the previous drug) should be observed before starting robenacoxib.
- Renal Perfusion: Use cautiously with drugs that affect renal blood flow (e.g., diuretics, ACE inhibitors) due to the risk of renal toxicity.
- Reproduction: Safety has not been established in pregnant or lactating animals; use is not recommended.
医薬品相互作用
Some NSAIDs can reduce effects on blood pressure
May increase the risk of gastrointestinal toxicity (e.g., ulceration, bleeding, vomiting, diarrhea)
May increase the risk of gastrointestinal toxicity (e.g., ulceration, bleeding, vomiting, diarrhea)
NSAIDs may increase serum levels
Administration has increased plasma levels of celecoxib in humans and potentially could also affect robenacoxib levels in dogs
NSAIDs may reduce the saluretic and diuretic effects
As robenacoxib is highly bound to plasma proteins (>99%), it may displace other highly bound drugs or be displaced by them, potentially leading to increased serum levels and toxicity
Serious toxicity has occurred when NSAIDs have been used concomitantly; use together with extreme caution
May enhance the risk of nephrotoxicity development
Increased risk of severe gastrointestinal ulceration and renal toxicity. Require a 3-5 day wash-out period.
Increased risk of severe gastrointestinal ulceration and bleeding.
Increased risk of nephrotoxicity.
監視
- Baseline and periodic physical examinations to assess clinical efficacy and adverse effects
- Baseline and periodic CBC, serum biochemistry (liver and renal function), electrolytes, and urinalysis
- For long-term therapy in dogs: Monitor liver enzymes at the start of therapy, and after 2, 4, and 8 weeks; then every 3-6 months
- Discontinue therapy if liver enzymes increase markedly or if accompanied by clinical signs (anorexia, apathy, vomiting)
- Clinical response (reduction in pain and inflammation)
- Gastrointestinal signs (monitor for vomiting, diarrhea, or melena)
- Renal parameters (BUN, Creatinine, USG) and hepatic enzymes, especially prior to anesthesia or during long-term therapy (>12 weeks)
薬物動態
半減期
吸収
Peak blood concentrations occur approximately 30 minutes after dosing in both dogs and cats. In dogs, food decreases peak levels somewhat. In cats, a small amount of food does not impact absorption.
分布
Highly bound to plasma proteins (>99%). Robenacoxib persists longer and at higher concentrations at sites of inflammation (e.g., inflamed joints) than in the central blood compartment.
代謝
Extensively metabolized by the liver in both dogs and cats. It does not appear to induce hepatic enzymes in dogs.
消失
In dogs, excretion is primarily biliary (~65%) with the remainder excreted renally. In cats, elimination is 70% biliary and 30% renal.
過剰投与
Acute overdoses may potentially cause gastrointestinal, kidney, or liver toxicity.
Interestingly, chronic toxicity studies in healthy young dogs (up to 10 mg/kg/day for 6 months) and cats (up to 10 mg/kg SC for 3 days) did not produce signs of toxicity.
Treatment: If an acute overdose occurs, symptomatic and supportive therapy is recommended. This may include the administration of gastrointestinal protective agents (e.g., sucralfate, omeprazole), IV fluid therapy for forced diuresis and renal support, and contacting an animal poison control center for guided management.
製品
製剤
- Flavored oral tablets (canine and feline)
- Solution for injection
- 5 mg flavoured tablets (dogs)
- 10 mg flavoured tablets (dogs)
- 20 mg flavoured tablets (dogs)
- 40 mg flavoured tablets (dogs)
- 6 mg flavoured tablets (cats)
- 20 mg/ml injectable solution
動物用医薬品
- Robenacoxib Flavored Oral Tablets (dogs): 5 mg, 10 mg, 20 mg, 40 mg
- Robenacoxib Flavored Tablets (cats): 6 mg
- Robenacoxib Solution for Injection: 20 mg/mL in 20 mL multi-dose vials
- Onsior 5 mg flavoured tablets for dogs
- Onsior 10 mg flavoured tablets for dogs
- Onsior 20 mg flavoured tablets for dogs
- Onsior 40 mg flavoured tablets for dogs
- Onsior 6 mg flavoured tablets for cats
- Onsior 20 mg/ml solution for injection
規制ステータス
POM-V classification
POM-V classification
規制データなし: 🇺🇸 US · 🇭🇰 HK · 🇹🇼 TW · 🇯🇵 JP · 🇰🇷 KR · 🇦🇺 AU
保管・安定性
Store canine flavored tablets at 25°C (77°F) or less. Store feline flavored tablets at no more than 30°C (86°F). The injection should be stored in the refrigerator (2°-8°C) in its original outer carton.
飼主向け情報
オンシオール® (ロベナコキシブ) は、ペットの痛みや炎症を和らげるために使用されるお薬です。安全かつ効果的に使用するために、以下のガイドラインに従ってください：
- 犬の場合：空腹時に与えてください。食事の少なくとも30分前または30分後に投薬してください。
- 猫の場合：食事なし、または少量の食事と一緒に与えることができます。錠剤を割ったり、砕いたりしないでください。
- 取り扱いの注意：薬を触った後は手を洗ってください。出産が近い妊婦の方は、この薬を取り扱う際に手袋を着用してください。
- 注意すべき症状：ペットに以下のような体調不良の兆候が見られた場合は、すぐに投薬を中止し、獣医師に連絡してください：
- 重度または血混じりの嘔吐や下痢
- 食欲不振や極度の無気力（ぐったりしている）
- 白目や歯茎の黄疸（黄色くなる）
- 虚脱や脱力感
- 獣医師の指示なしに、この薬を服用している間は、他の痛み止め（アスピリン、イブプロフェン、その他の動物用NSAIDなど）やステロイドを絶対に与えないでください。
VetSheet医薬品リファレンスは獣医専門家の臨床意思決定支援を目的としており、専門的判断または製造業者の最新医薬品情報の代替にはなりません。